Alector LLC

Herve Rhinn

Arnon Rosenthal

Tina Schwabe

Angie Grace Yee

Ilaria Tassi

Philip Ling Kong

Muhammad Abbas Alhawagri

Eric Brown

Jeonghoon Sun

Wei-Hsien Ho

Seung-Joo Lee

Helen Lam

Kate Monroe

Francesca Avogadri-Connors

Hua Long

William Monteith

Ananya Mitra

Karpagam Srinivasan

Santiago Viveros Salazar

Daniel P Bermingham

Francesca Cignarella

Klaus-Dieter Heger

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-MS4A4A antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, antibody fragments, etc., that specifically bind a TMEM106B polypeptide, e.g., a mammalian TMEM106B or human TMEM106B, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-TMEM106B antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A6A polypeptide, e g., a mammalian MS4A6A or human MS4A6A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-MS4A6A antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-CD33 antibodies and methods of use thereof

Growing community of inventors

San Francisco, CA, United States of America

Herve Rhinn